Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 40, Novembre 2024
Les Cahiers de Myologie
|
|
|---|---|---|
| Page(s) | 22 - 25 | |
| Section | Prix SFM | |
| DOI | https://doi.org/10.1051/medsci/2024132 | |
| Publié en ligne | 18 novembre 2024 | |
- Barraud C, Desguerre I, Barnerias C, et al. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve 2018 ; 57 (4) : 603–609. [CrossRef] [PubMed] [Google Scholar]
- Anlar B. Juvenile Myasthenia. Paediatr Drugs 2000 ; 2 (3) : 161–9. [CrossRef] [PubMed] [Google Scholar]
- Zingariello CD, Elder ME, Kang PB. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis. Pediatr Neurol 2020 ; 111 : 40–43. [CrossRef] [PubMed] [Google Scholar]
- Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 2020 ; 96 (3) : 114–122. [Google Scholar]
- Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurol 2020 ; 77 (8) : 974–981. [CrossRef] [PubMed] [Google Scholar]
- Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006 ; 6 (5 Pt 1) : 859–866. [CrossRef] [PubMed] [Google Scholar]
- Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 2017 ; 89 (10) : 1069–1077. [CrossRef] [PubMed] [Google Scholar]
- Fichtner ML, Jiang R, Bourke A, et al. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front Immunol 2020 ; 11 : 776. [CrossRef] [PubMed] [Google Scholar]
- Hachiya Y, Uruha A, Kasai-Yoshida E, et al. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. J Neuroimmunol 2013 ; 265 (1-2) : 128–130. [CrossRef] [PubMed] [Google Scholar]
- McAtee CL, Lubega J, Underbrink K, et al. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open 2021 ; 4 (2) : e2036321. [CrossRef] [PubMed] [Google Scholar]
- Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 2022 ; 79 (11) : 1105–1112. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.